52785-3 |
Maximum lysis.extrinsic coagulation system activated.fibrinolysis suppressed |
LenFr |
Bld |
Pt |
Qn |
Thromboelastography.rotational |
|
ACTIVE |
Maximum lysis.extrinsic coagulation system activated.fibrinolysis suppressed [Length fraction] in Blood by Rotational TEG |
|
MIN |
DefinitionDescription |
|
|
% |
90% |
|
|
|
|
|
COAG |
|
52785-3 |
|
Thromboelastography.rotational |
|
|
Observation |
|
|
|
0 |
ML.fibrinolysis supp LenFr Bld ROTEM |
|
|
|
N |
|
Activ; Blood; Coag; Hematology; Heme; Length Fraction; ML; ML.extrinsic; ML.fibrinolysis supp; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; ROTEM; TEG; TEM; Thrombelastography; Thrombelastometry; Thromboelastometry; WB; Whole blood |
2.73 |
2.24 |
|
|
|
|
|
|
|
% |
|
|
Updated Method from Thromboelastography to clarify that the Method used for this assay is rotational TEG ("ROTEM") and to distinguish from the original thromboelastography and new resonance thromboelastography Methods. |
0 |
52786-1 |
Maximum lysis.extrinsic coagulation system activated |
LenFr |
Bld |
Pt |
Qn |
Thromboelastography.rotational |
|
ACTIVE |
Maximum lysis.extrinsic coagulation system activated [Length fraction] in Blood by Rotational TEG |
|
MIN |
DefinitionDescription |
|
|
% |
90% |
|
|
|
|
|
COAG |
|
52786-1 |
|
Thromboelastography.rotational |
|
|
Observation |
|
|
|
0 |
ML.extrinsic LenFr Bld ROTEM |
|
|
|
N |
|
Activ; Blood; Coag; Hematology; Heme; Length Fraction; ML; ML.extrinsic; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; ROTEM; TEG; TEM; Thrombelastography; Thrombelastometry; Thromboelastometry; WB; Whole blood |
2.73 |
2.24 |
|
|
|
|
|
|
|
% |
|
|
Updated Method from Thromboelastography to clarify that the Method used for this assay is rotational TEG ("ROTEM") and to distinguish from the original thromboelastography and new resonance thromboelastography Methods. |
0 |
52787-9 |
Maximum lysis.intrinsic coagulation system activated |
LenFr |
Bld |
Pt |
Qn |
Thromboelastography.rotational |
|
ACTIVE |
Maximum lysis.intrinsic coagulation system activated [Length fraction] in Blood by Rotational TEG |
|
MIN |
DefinitionDescription |
|
|
% |
80% |
|
|
|
|
|
COAG |
|
52787-9 |
|
Thromboelastography.rotational |
|
|
Observation |
|
|
|
0 |
ML.intrinsic LenFr Bld ROTEM |
|
|
|
N |
|
Activ; Blood; Coag; Hematology; Heme; Length Fraction; ML; ML.intrinsic; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; ROTEM; TEG; TEM; Thrombelastography; Thrombelastometry; Thromboelastometry; WB; Whole blood |
2.73 |
2.24 |
|
|
|
|
|
|
|
% |
|
|
Updated Method from Thromboelastography to clarify that the Method used for this assay is rotational TEG ("ROTEM") and to distinguish from the original thromboelastography and new resonance thromboelastography Methods. |
0 |
52788-7 |
Maximum lysis.intrinsic coagulation system activated.heparin insensitive |
LenFr |
Bld |
Pt |
Qn |
Thromboelastography.rotational |
|
ACTIVE |
Maximum lysis.intrinsic coagulation system activated.heparin insensitive [Length fraction] in Blood by Rotational TEG |
|
MIN |
DefinitionDescription |
|
|
% |
90% |
|
|
|
|
|
COAG |
|
52788-7 |
|
Thromboelastography.rotational |
|
|
Observation |
|
|
|
0 |
ML.heparin insens LenFr Bld ROTEM |
|
|
|
N |
|
Activ; Blood; Coag; Hematology; Heme; Hep; Hepar; Heparn; Length Fraction; ML; ML.heparin insens; ML.intrinsic; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; ROTEM; TEG; TEM; Thrombelastography; Thrombelastometry; Thromboelastometry; WB; Whole blood |
2.7 |
2.24 |
|
|
|
|
|
|
|
% |
|
|
Updated Method from Thromboelastography to clarify that the Method used for this assay is rotational TEG ("ROTEM") and to distinguish from the original thromboelastography and new resonance thromboelastography Methods. |
0 |
52789-5 |
Clot initiation |
Time |
Bld |
Pt |
Qn |
Thromboelastography |
|
ACTIVE |
Clot initiation [Time] in Blood by Thromboelastography |
|
MIN |
DefinitionDescription |
|
|
s |
300 sec |
|
|
|
|
|
COAG |
|
52789-5 |
|
Thromboelastography |
|
|
Both |
|
|
|
0 |
Clot init Bld TEG |
|
|
|
N |
|
Blood; COAGULATION; Hematology; Heme; Point in time; QNT; Quan; Quant; Quantitative; Random; TEG; Thrombelastography; Thrombelastometry; WB; Whole blood |
2.73 |
2.24 |
|
|
|
|
|
|
|
s |
|
|
Release 2.70: COMPONENT: Updated from "Clotting time" to more accurately represent what is being measured; Release 2.67: ORDER_OBS: Updated Order_Obs from "Observation" to "Both" |
0 |
5279-5 |
Plasmodium sp Ab |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Plasmodium sp Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
5279-5 |
|
|
|
|
Both |
|
|
|
0 |
Plasmodium Ab Ser-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; ID; Infectious Disease; InfectiousDisease; Malaria; Malarial; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; species; spp; SR |
2.69 |
1 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
52790-3 |
Guidance for percutaneous replacement of drainage catheter |
Find |
Abdomen |
Pt |
Doc |
CT |
|
ACTIVE |
CT Guidance for percutaneous replacement of drainage catheter of Abdomen |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
52790-3 |
|
CT |
|
|
Both |
|
|
|
0 |
CT Guided Abd PC drain cath replace |
|
|
|
N |
|
Abd; Abdo; Abdomen+; Abdominal; CAT scan; Cath; Computed tomography; Computerized tomography; CT scan; Document; Drain; Exudate; Finding; Findings; Guid; Guide; Guided; Imaging; PC drain cath replace; Perc; Point in time; Rad; RADIOLOGY; Random; Removal of fluid |
2.68 |
2.24 |
|
|
|
|
|
|
|
|
|
|
Release 2.68: COMPONENT: Updated "drainage tube" to "drainage catheter", the preferred name in the LOINC/RadLex unified model.; Previous Releases: The scale has been changed from "Nar" to "Doc" to fit with the CDA model.;Updated component from "Guidance for replacement of percutaneous drainage tube" based on LOINC/Radlex unified model |
0 |
52791-1 |
Guidance for percutaneous replacement of drainage catheter |
Find |
Pelvis |
Pt |
Doc |
CT |
|
ACTIVE |
CT Guidance for percutaneous replacement of drainage catheter of Pelvis |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
52791-1 |
|
CT |
|
|
Both |
|
|
|
0 |
CT Guided Pelvis PC drain cath replace |
|
|
|
N |
|
CAT scan; Cath; Computed tomography; Computerized tomography; CT scan; Document; Drain; Exudate; Finding; Findings; Guid; Guide; Guided; Imaging; PC drain cath replace; Pelvic; Perc; Point in time; Rad; RADIOLOGY; Random; Removal of fluid |
2.68 |
2.24 |
|
|
|
|
|
|
|
|
|
|
Release 2.68: COMPONENT: Updated "drainage tube" to "drainage catheter", the preferred name in the LOINC/RadLex unified model.; Previous Releases: The scale has been changed from "Nar" to "Doc" to fit with the CDA model.; Updated Component from "Guidance for replacement of percutaneous drainage tube" based on LOINC/RadLex unified model |
0 |
52792-9 |
Rh |
Type |
Bld^Father |
Pt |
Nom |
|
|
ACTIVE |
Father's Rh Type |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
52792-9 |
|
|
|
|
Both |
|
|
|
0 |
Rh Bld Father |
|
|
|
N |
|
Blood; BLOOD BANK; D phenotyping; D typing; Hematology; Heme; Nominal; Point in time; Random; Rh phenotyping; Rh typing; Typ; WB; Whole blood |
2.61 |
2.24 |
|
|
|
|
|
|
|
|
|
|
|
0 |
52793-7 |
ABO group |
Type |
Bld^Father |
Pt |
Nom |
|
|
ACTIVE |
Father's ABO group Type |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
52793-7 |
|
|
|
|
Both |
|
|
|
0 |
ABO Group Bld Father |
|
|
|
N |
|
Blood; BLOOD BANK; Hematology; Heme; Nominal; Point in time; Random; Typ; WB; Whole blood |
2.72 |
2.24 |
|
|
|
|
|
|
|
|
|
|
|
0 |
52794-5 |
Ova & parasites^3rd specimen |
Prid |
XXX |
Pt |
Nom |
Microscopy.light |
|
ACTIVE |
Ova and parasites identified in Specimen by Light microscopy--3rd specimen |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
52794-5 |
|
Microscopy.light |
|
|
Both |
|
|
|
0 |
O+P sp3 Spec Micro |
|
|
|
N |
|
ID; Identity or presence; Infectious Disease; InfectiousDisease; LM; Micro; Microbiology; Micros; Microscopic; Misc; Miscellaneous; Nominal; O&P; O+P; Other; Ova and parasite; Ovum; Parasite; Point in time; Random; sp3; Spec; To be specified in another part of the message; Unspecified |
2.78 |
2.24 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; Previous Releases: Changed model to make term consistent with other terms |
0 |
52795-2 |
Ova & parasites^2nd specimen |
Prid |
XXX |
Pt |
Nom |
Microscopy.light |
|
ACTIVE |
Ova and parasites identified in Specimen by Light microscopy--2nd specimen |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
52795-2 |
|
Microscopy.light |
|
|
Both |
|
|
|
0 |
O+P sp2 Spec Micro |
|
|
|
N |
|
Convalescent; ID; Identity or presence; Infectious Disease; InfectiousDisease; LM; Micro; Microbiology; Micros; Microscopic; Misc; Miscellaneous; Nominal; O&P; O+P; Other; Ova and parasite; Ovum; Parasite; Point in time; Post immunization; Random; Second; sp2; Spec; To be specified in another part of the message; Unspecified |
2.78 |
2.24 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; Previous Releases: Changed model to make term consistent with other terms |
0 |
52796-0 |
Planned stop date |
Date |
Medication.current |
Pt |
Qn |
|
|
DISCOURAGED |
Planned stop date Current medication |
|
MIN |
DefinitionDescription |
|
|
MMDDYY |
|
|
|
|
|
|
SURVEY.CARE |
|
52796-0 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
CARE Survey; Med; Point in time; QNT; Quan; Quant; Quantitative; Random; Survey |
2.64 |
2.26 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
52797-8 |
Diagnosis ICD code |
Prid |
^Patient |
Pt |
Nom |
|
|
ACTIVE |
Diagnosis ICD code [Identifier] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CLIN |
|
52797-8 |
|
|
|
|
Both |
|
|
|
0 |
Dx ICD code |
|
|
|
N |
|
CLIN; Dx; Dx ICD code; Identity or presence; International Classification of Diseases; Nominal; Point in time; Random |
2.73 |
2.26 |
|
|
|
|
|
|
|
|
|
|
Changed CLASS from SURVEY.MDS to CLIN |
0 |
52798-6 |
Medical coding diagnosis, comorbidity, and complication list is complete |
Find |
^Patient |
Pt |
Ord |
CARE |
|
DEPRECATED |
Deprecated Medical coding diagnosis, comorbidity, and complication list is complete |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.CARE |
|
52798-6 |
|
CARE |
|
|
|
|
|
|
0 |
|
|
CARE I.b16 |
Is this list complete? |
N |
|
CARE Survey; Continuity assessment record and evaluation; Dx; Finding; Findings; Medical coding Dx, comorbidity, and complication list is complete; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Survey |
2.36 |
2.26 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
52799-4 |
Major treatments used on or 1D prior to day of death panel |
- |
^Patient |
Pt |
- |
|
|
ACTIVE |
Major treatments used on or 1 day prior to day of death panel |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CARE |
|
52799-4 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
CARE Survey; Continuity Assessment Record and Evaluation (CARE) Pnl; Major Txs; Major Txs used on or 1D prior to day of death; Major Txs used on or 1D prior to day of death panel; Pan; Panl; Pnl; Point in time; Random; Survey; Tx; Txs |
2.48 |
2.26 |
|
|
|
|
|
|
|
|
|
|
|
0 |
528-0 |
Viomycin |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Viomycin [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
528-0 |
|
MIC |
|
|
Observation |
|
|
|
0 |
Viomycin Islt MIC |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Tuberactinomycin b |
2.19 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
5280-3 |
Plasmodium vivax Ab |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Plasmodium vivax Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
5280-3 |
|
|
|
|
Both |
|
|
|
0 |
P vivax Ab Ser-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; ID; Infectious Disease; InfectiousDisease; Malaria; Malarial; Microbiology; P vivax; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.69 |
1 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
52800-0 |
Major treatments used on or 1D prior to day of death |
Find |
^Patient |
Pt |
Nom |
CARE |
|
DISCOURAGED |
Major treatments used on or 1 day prior to day of death [CARE] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.CARE |
|
52800-0 |
|
CARE |
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
CARE Survey; Continuity assessment record and evaluation; Finding; Findings; Major Txs; Major Txs used on or 1D prior to day of death; Nominal; Point in time; Random; Survey; Tx; Txs |
2.64 |
2.26 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
52801-8 |
Major treatments admitted with panel |
- |
^Patient |
Pt |
- |
|
|
ACTIVE |
Major treatments admitted with panel |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CARE |
|
52801-8 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
CARE Survey; Continuity Assessment Record and Evaluation (CARE) Pnl; Major Txs; Major Txs admitted with; Major Txs admitted with panel; Pan; Panl; Pnl; Point in time; Random; Survey; Transferred; Tx; Txs |
2.48 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
52802-6 |
Major treatments admitted with |
Find |
^Patient |
Pt |
Nom |
CARE |
|
DISCOURAGED |
Major treatments admitted with [CARE] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.CARE |
|
52802-6 |
|
CARE |
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
CARE Survey; Continuity assessment record and evaluation; Finding; Findings; Major Txs; Major Txs admitted with; Nominal; Point in time; Random; Survey; Transferred; Tx; Txs |
2.64 |
2.27 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
52803-4 |
Major treatments discharged with panel |
- |
^Patient |
Pt |
- |
|
|
DISCOURAGED |
Major treatments discharged with panel |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CARE |
|
52803-4 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
CARE Survey; Continuity Assessment Record and Evaluation (CARE) Pnl; Major Txs; Major Txs discharged with; Major Txs discharged with panel; Pan; Panl; Pnl; Point in time; Random; Survey; Tx; Txs |
2.64 |
2.27 |
|
Panel |
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
52804-2 |
Major treatments discharged with |
Find |
^Patient |
Pt |
Nom |
CARE |
|
DISCOURAGED |
Major treatments discharged with [CARE] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.CARE |
|
52804-2 |
|
CARE |
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
CARE Survey; Continuity assessment record and evaluation; Finding; Findings; Major Txs; Major Txs discharged with; Nominal; Point in time; Random; Survey; Tx; Txs |
2.64 |
2.27 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
52805-9 |
Major treatments used within 2D interim period panel |
- |
^Patient |
2D |
- |
|
|
DISCOURAGED |
Major treatments used within 2 days interim period panel |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CARE |
|
52805-9 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
2 days; 48 hours; CARE Survey; Continuity Assessment Record and Evaluation (CARE) Pnl; Major Txs; Major Txs used within 2D interim period; Major Txs used within 2D interim period panel; Pan; Panl; Pnl; Survey; Tx; Txs |
2.64 |
2.26 |
|
Panel |
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
52806-7 |
Major treatments used within 2D interim period |
Find |
^Patient |
2D |
Nom |
CARE |
|
DISCOURAGED |
Major treatments used within 2 days interim period [CARE] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.CARE |
|
52806-7 |
|
CARE |
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
2 days; 48 hours; CARE Survey; Continuity assessment record and evaluation; Finding; Findings; Major Txs; Major Txs used within 2D interim period; Nominal; Survey; Tx; Txs |
2.64 |
2.26 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |